Clinical Trials Logo

Clinical Trial Summary

This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter density. The imaging data coupled with family history and environmental exposure data may provide important information about potential risk factors for parkinsonian syndrome.


Clinical Trial Description

The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.

On the first day participants are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain. Study participants will also have a thorough neurologic examination and standard neuropsychological testing, including testing of memory, concentration, abstraction and visual spatial functions.

Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure will be used to obtain SPECT (single photon emission computed tomography) images of the brain.

Participants may be contacted to repeat these procedures every 12 to 18 months. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT00117819
Study type Interventional
Source Institute for Neurodegenerative Disorders
Contact
Status Completed
Phase Phase 2
Start date March 2001
Completion date January 2013

See also
  Status Clinical Trial Phase
Completed NCT00132626 - Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome Phase 2
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Completed NCT00096876 - A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
Completed NCT00117195 - A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease N/A
Completed NCT04193527 - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Phase 3
Completed NCT04974034 - Movement Disorders Analysis Using a Deep Learning Approach
Completed NCT00354003 - The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
Completed NCT04925622 - Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Completed NCT00315250 - Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease Phase 2
Completed NCT00273351 - Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families Phase 2
Completed NCT00129181 - Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease N/A
Completed NCT00096720 - Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease Phase 2
Completed NCT00129675 - Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty Phase 2
Recruiting NCT05110547 - Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions